Premium
Soluble p185 HER‐2 in patients with malignant bone tumours
Author(s) -
Holzer G.,
Pfandlsteiner T.,
Koschat M.,
Noske H.,
Trieb K.,
Kotz R.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20217
Subject(s) - osteosarcoma , medicine , sarcoma , predictive value , chemotherapy , bone tumours , ewing's sarcoma , pathology , oncology
Background This study was initiated to test the hypothesis that soluble p185 HER‐2 could be of value as a diagnostic or predictive marker for patients with malignant bone tumours. Procedure Sera of 35 patients with high‐grade malignant osteosarcoma (n = 27) and Ewing Sarcoma (n = 8) were tested at the time of diagnosis by ELISA and compared with sera of controls (n = 38) and clinical data. Results In patients with osteosarcoma and Ewing Sarcoma, levels of sp185 HER‐2 did not differ significantly from levels in controls. These results were irrespective of the type of tumour, survival chemotherapy or other clinical variables. Conclusion p185 HER‐2 serum levels do not appear to be of diagnostic or predictive value for differentiation of high‐grade osteosarcoma and Ewing Sarcoma. © 2004 Wiley‐Liss, Inc.